The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
Advanced biliary tract adenocarcinoma has a poor prognosis with limited therapeutic options.
Nab-paclitaxel plus S-1 chemotherapy will be given to untreated patients with advanced
biliary tract adenocarcinoma for the first-line treatment.